Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our top-notch dedicated system is used to design specialised libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q86Y82

UPID:
STX12_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
Q86Y82; B1AJQ7; O95564

BACKGROUND:
Syntaxin-12 is integral to the SNARE complex, facilitating the fusion of transport vesicles with their target membranes. This protein, in collaboration with SNARE STX6, is essential for the endocytic recycling pathway, ensuring the proper movement of vesicles to the cell membrane. Its interaction with GRIP1, GRIA2, and NSG1 plays a significant role in the regulation of AMPAR's intracellular fate and the endosomal sorting of GRIA2, highlighting its importance in membrane targeting and recycling processes.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Syntaxin-12 offers a promising avenue for the development of novel therapeutic approaches, focusing on its key role in vesicle transport and membrane fusion, which are vital for maintaining cellular function and communication.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.